MindMaze Therapeutics Holding

MindMaze Therapeutics Holding SA is a Swiss-based, commercial-stage biopharmaceutical and neurotechnology company formed in December 2025 through the business combination of RELIEF THERAPEUTICS Holding SA and NeuroX Group SA (the successor to MindMaze). The company develops and commercializes first-of-its-kind digital neurotherapeutics alongside a portfolio of biopharmaceutical assets targeting rare diseases. Its FDA-cleared and CE-marked digital suite includes the MindPod immersive in-clinic therapy system, MindMotion GO for home-based rehabilitation, the Izar hand-therapy device, and Physilog clinical-grade motion sensors, all underpinned by an advanced AI-driven brain technology platform. Additionally, the company manages a pipeline of clinical and commercial biopharmaceutical assets addressing rare dermatological, metabolic, and respiratory conditions, such as RLF-TD011 for epidermolysis bullosa and RLF-OD032 for phenylketonuria. MindMaze Therapeutics is publicly traded on the SIX Swiss Exchange under the ticker MMTX.